News Posts List
Meet Houston's smallest police officer
12/10/2014
The Houston Police Department has made sure that a six-year-old girl fighting cancer has been able to live out one of her biggest dreams
A conversation with a cancer patient about palliative care
12/09/2014
End-of-life-care expert Timothy Quill carries out a discussion with neurosurgeon Paul Kalanithi who was diagnosed in 2013 with advanced-stage lung cancer.
Kidney cancer shock figures
12/09/2014
The number of cases of kidney cancer diagnosed each year in Great Britain has risen over 9,000 for the first time, new figures from Cancer Research UK show today.
Immune Checkpoint Tx Takes Down Ca
12/09/2014
Treatment with an immune checkpoint inhibitor led to consistent responses across multiple types of cancer...
Don’t ignore cancer symptoms, says study
12/04/2014
Most people with potential warning symptoms don’t have cancer, but some will and others may have other diseases that would benefit from early attention.
Exciting Product Development Developments For Provectus' Lead Drug
12/04/2014
Its lead drug, PV-10, is now part of the immunotherapy cancer treatment revolution
Fargo, ND, mayor known for flood fights dies at 73
12/04/2014
Fargo, North Dakota, Mayor Dennis Walaker, the man known as the "flood mayor" for leading the state's largest city through several successful fights against the Red River, died Tuesday at his home.
Navigating the Treatment Landscape
12/03/2014
For the patient with advanced-stage kidney cancer, deciding on a course of treatment presents diverse choices...
Will you provide feedback on the features, functions and navigability of mobile healthcare apps?
11/25/2014
If you are a kidney cancer patient, 18 years of age or older, and you live in the NYC or Philadelphia area, we invite you to participate in this research. Interviews will take approximately 45 minutes and can be conducted at a location near your home between Dec 15 - 19, 2014.
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Typ
11/25/2014
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R).
News Feed